Vasculitis and Giant Cell Arteritis News

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.

An growing therapeutic armamentarium for antineutrophil cytoplasmic antibody-associated vasculitis — including avacopan and azathioprine — is providing rheumatologists with an increasingly robust array of options, according to a presenter.

Glucocorticoids are an effective go-to treatment for giant cell arteritis, but discontinuing them can be difficult, according to a presenter at the 2024 AWIR annual conference.

Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.

It has been at least 2 years since the first cohort of patients with lupus underwent chimeric antigen receptor T-cell treatment, and, at least so far, for every one of them, each new dawn represents another day spent in full remission.

KIAWAH ISLAND, S.C. — Temporal artery ultrasound and EULAR score are reliable means for diagnosing giant cell arteritis, Mercy Bechtold, MD, said during her presentation at Kiawah Eye.

CLEVELAND — In this video perspective from the Cleveland Clinic’s Medical Dermatology Therapy Update III meeting, Adam Brown, MD, a rheumatologist at the institution, discusses what to look for in leukocytoclastic, or cutaneous, vasculitis.

DESTIN, Fla. — Rheumatologists should consider tapering tocilizumab for patients with giant cell arteritis in remission despite the increased risk for flare, said a speaker at the Congress of Clinical Rheumatology East annual meeting.

DESTIN, Fla. — Treating respiratory and systemic manifestations of eosinophilic granulomatosis with polyangiitis can be effective despite an incomplete understanding of the disease, said a speaker at the Congress of Clinical Rheumatology East.